摘要
目的探讨辛伐他汀对2型糖尿病肾病患者磷脂肌醇信号途径-酰甘油（protein kinase C／diacylglycerol，DAG／PKC）信号通路及丝裂原活化蛋白激酶（mitogen-activated protein kinase，MAPK）信号通路的影响。方法选择2010年6月到2014年12月在黄石市中心医院住院、并且经。肾活检确诊为2型糖尿病肾病的16例患者，住院后给予辛伐他汀治疗3个月，随后抽取患者血液15ml，用全自动生化仪检测肾功能，相关试剂盒检测血脂、白细胞介素1α（interleukin-1α，IL-1α）、IL-6、IL-1β及肿瘤坏死因子α（tumor necrosis factors α，TNF-α）等，比较治疗前后DAG／PKC信号通路以及MAPK信号通路相关酶蛋白表达。结果16例患者血尿素氮、血肌酐以及血尿酸三个指标治疗后较治疗前明显降低（P〈0．05），肌酐清除率治疗后明显高于治疗前（P〈0．05），总胆固醇、三酰甘油、低密度脂蛋白胆固醇三个指标治疗后明显低于治疗前（P〈0．05），高密度脂蛋白胆固醇含量治疗后明显高于治疗前；炎性因子IL-1α、IL-1β、IL-6以及TNF-α治疗后明显低于治疗前（P〈0．05）；PKC-η及PKC-ζ蛋白及mRNA表达，治疗后明显低于治疗前（P〈O．05）；MAPK、MKK以及MAKK蛋白和mRNA表达，治疗后明显低于治疗前（P〈0．05）。结论辛伐他汀可明显改善2型糖尿病肾病患者肾功能，其机制可能是通过调控DAC-PKC及MAPK信号通路改善。肾功能。
Objective To investigate the effect of simvastatin on the DAG/PKC and MAPK sig- naling pathways in type 2 diabetic nephropathy patients. Methods 16 patients with diabetic nephropathy were treated from June 2010 to December 2014 in Huangshi Central Hospital. These patients given simvastatin. After treatment for 3 months, 15 mL blood was collected from each patient. Automatic biochemical analyzer was used to determine renal function parameters, and a kit was used to detected serum lipids, IL-1α, IL-6, IL-1β and TNF-α. The expression of DAG/PKC and MAPK signaling pathway-related enzyme proteins was compared before and after treatment. Results After treatment, blood urea nitrogen, serum creatinine and serum uric acid were reduced significantly in patients after treatment as compared with in patients before treatment （P〈0. 05）. The endogenous creinine clearance rate in patients after treatment was significantly higher than in patients before treatment （P〈 0. 05）. CHOL, TG and LDL-C levels in patients after treatment was significantly lower than in patients before treatment （P〈0. 05）. The HDL-C level in patients after treatment was significantly higher than in patients before treatment. The levels of inflammatory cytokines （IL-1α, IL-1β, IL-6 and TNF-α） were significantly lower in patients after treatment than in patients before treatment （P〈 0. 05）. The expression of PKC-η and PKC-ζ protein and mRNA was significantly lower in patients after treatment than in patients before treatment. The expression levels of MAPK, MKK, and MAKK protein and mRNA in patients after treatment was significantly lower than in patients before treatment （P〈0. 05）. Conclusions Simvastatin can improve renal function in type 2 diabetic nephropathy pa tients by regulating DAG-PKC and MAPK signaling pathway.
出处
《临床肾脏病杂志》
2015年第2期82-85,共4页
Journal Of Clinical Nephrology
基金
湖北省卫生厅资助项目(NO.2012FFA016)
